Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27334854 | 0.70 | KDM4E (0.64) | TDP1KDM4EALOX15APEX1KMT2A | |
| Carmoxirole SCHEMBL31723392 | 0.70 | TDP1 (0.98) | TDP1KDM4EALOX15APEX1KMT2A | |
| Carmoxirole SCHEMBL146312 | 0.70 | TDP1 (0.98) | TDP1KDM4EALOX15APEX1KMT2A | |
| Carmoxirole SCHEMBL5606162 | 0.70 | TDP1 (0.98) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9256337 | 0.69 | HTR7 (0.70) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9581606 | 0.69 | TDP1 (0.96) | TDP1KDM4EALOX15APEX1KMT2A | |
| Carmoxirole SCHEMBL1231058 | 0.69 | TDP1 (1.00) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL5432115 | 0.69 | HTR7 (0.82) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL8537712 | 0.69 | MPO (0.67) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9582127 | 0.69 | TDP1 (0.84) | TDP1KDM4EALOX15APEX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877755-B2 | Dopamine-agonist combination therapy for improving sleep quality | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20100004251-A1 | Dopamine-Agonist Combination Therapy For Improving Sleep Quality | SEPRACOR INC. (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1742624-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20050267176-A1 | Dopamine-agonist combination therapy for improving sleep quality | SEPRACOR INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005079851-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | SEPRACOR, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267176-A1 | Dopamine-agonist combination therapy for improving sleep quality | DRD2, DRD1, HTR5A | TDP1 2656/4885KDM4E 342/4885ALOX15 2470/4885 |
| US-20100004251-A1 | Dopamine-Agonist Combination Therapy For Improving Sleep Quality | DRD2, DRD1, DRD3 | TDP1 2648/4885KDM4E 346/4885ALOX15 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.